Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 49

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 49
---
 and inventory ramp-up.

Net
Cash Used in Investing Activities – During the six months ended September 30, 2025, net cash used in investing activities
was $6,605. This cash used in investing activities was primarily attributable to the purchase of equipment.

Net
Cash Provided by Financing Activities – During the six months ended September 30, 2025, net cash provided by financing
activities of $4,361,829 consisted of proceeds of Series B preferred stock receivable of $4,400,000, proceeds from the issuance of convertible
debentures of $160,000 and proceeds from the exercise of a warrant of $140,000.

OFF-BALANCE
SHEET ARRANGEMENTS

As
of September 30, 2025, and as of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are
reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses,
results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 29 

GOING
CONCERN

The
report of independent registered public accounting firm accompanying our September 30, 2025 financial statements contain an explanatory
paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared
assuming that we will continue as a going concern, which contemplates that we will realize our assets and satisfy our liabilities and
commitments in the ordinary course of business. Our working capital at September 30, 2025, was $1,057,029. As a result of our private
placement offering with proceeds of $5,000,000 from the sale of Series B convertible preferred stock, we believe the proceeds from this
private placement offering are sufficient to fund operations until December 31, 2025 (see Liquidity and Capital Resources above).

We
have continued to realize losses from operations. We will need to raise additional capital in the future to support our efforts to
commercialize Spryng® and PrecisePRP™ products and our ongoing operations. We expect to continue to raise additional
capital through the sale of our securities from time to time for the foreseeable future to fund our business expansion. Our ability
to obtain such additional capital will likely be subject to various factors, including our overall business performance and market
conditions. There can be no guarantee that the Company will be successful in its ability to raise additional capital